Kikkawa F, Ishikawa H, Tamakoshi K, Suganuma N, Mizuno K, Kawai M, Arii Y, Tamakoshi A, Kuzuya K, Tomoda Y
Department of Obstetrics and Gynecology, Nagoya University School of Medicine, Japan.
J Surg Oncol. 1995 Dec;60(4):227-31. doi: 10.1002/jso.2930600403.
Between 1989 and 1991, 150 patients with ovarian cancer were treated with chemotherapy, including cisplatin, in the Tokai Ovarian Tumor Study Group. Of these patients, 25 underwent cytoreductive surgery with lymphadenectomy, including removal of either pelvic or para-aortic lymph nodes, and 36 underwent both lymphadenectomies. A significant difference was observed between survival curves of the groups with positive and negative lymph nodes, respectively (P = 0.0049). The overall survival was longer in the lymphadenectomy group than in the nonlymphadenectomy group (P = 0.0842), and a significantly longer survival time was noted for stage III patients who underwent lymphadenectomy compared with those who did not (P = 0.0185). Multivariate analysis demonstrated that lymphadenectomy is a positive prognostic factor. The authors conclude that both pelvic and para-aortic lymph nodes should be resected to improve survival as well as to assess exact staging in patients with ovarian cancer.
1989年至1991年间，东海卵巢肿瘤研究组对150例卵巢癌患者进行了包括顺铂在内的化疗。在这些患者中，25例接受了包括盆腔或腹主动脉旁淋巴结切除在内的细胞减灭术及淋巴结清扫术，36例接受了双侧淋巴结清扫术。分别观察到淋巴结阳性组和阴性组生存曲线之间存在显著差异（P = 0.0049）。淋巴结清扫术组的总生存期长于未行淋巴结清扫术组（P = 0.0842），与未行淋巴结清扫术的III期患者相比，行淋巴结清扫术的III期患者生存期显著延长（P = 0.0185）。多因素分析表明淋巴结清扫术是一个积极的预后因素。作者得出结论，为提高生存率并准确评估卵巢癌患者的分期，应切除盆腔和腹主动脉旁淋巴结。
